Ureteroscope Market Advances as Dornier and Ambu Secure Key U.S. Clearances

Lede

Two major developments in ureteroscopy technologies the U.S. launch of Dornier MedTech America’s integrated ureteral access sheath and flexible ureteroscope system, and the FDA 510(k) clearance for Ambu’s single-use digital ureteroscope underscore a pivotal moment in the ureteroscope market. Collectively these advances highlight accelerated innovation in device design and workflow efficiency, growing interest in single-use solutions, and evolving priorities around sustainability, clinical value, and operational efficiency.

1. Dornier MedTech Launches Integrated Ureteral Access Sheath and Ureteroscope in the U.S.

Dornier MedTech America has received U.S. Food and Drug Administration clearance and launched two new devices designed to enhance the performance and procedural efficiency of flexible ureteroscopy: the Dornier Hoover Flexible and Navigable Suction (FANS) Ureteral Access Sheath and the Dornier Axis II Slim single-use ureteroscope. When combined with Dornier’s Thulio pulsed Thulium:YAG laser featuring RealPulse technology, the new system provides a fully integrated solution for stone dusting, fragmentation, irrigation, suction, and fragment removal. The Hoover FANS sheath offers continuous irrigation and suction while stabilizing the working channel, and the Axis II Slim scope with a 5.6 French distal tip delivers enhanced visualization and deflection within the kidney. Dornier executives emphasize that the duo of suction performance and instrument maneuverability enables urologists to perform flexible ureteroscopy more efficiently by maintaining clear visual fields and improving fragment clearance. Peer-reviewed in-vitro data suggest the system’s suction and deflection performance compare favorably to similar devices, potentially allowing smoother access to challenging calyces and faster case turnover. From a clinical workflow standpoint, the integrated system reflects a broader trend in the Ureteroscope Market toward comprehensive, procedure-oriented tool sets that combine imaging, energy delivery, and fragment clearance into a single, adaptable setup.

2. FDA Clears Ambu’s Single-Use Ureteroscope, Expanding Disposable Options

In a parallel development, the U.S. Food and Drug Administration granted 510(k) clearance to Ambu’s aScope 5 Uretero, a single-use digital flexible ureteroscope, along with its companion aBox 2 full-HD endoscopy system. The system previously received regulatory clearance in Europe and is now positioned for phased U.S. introduction, initially through select healthcare centers ahead of broader distribution. Ambu leadership frames the clearance as part of an ongoing shift in the Ureteroscope Market toward single-use solutions devices that address concerns about infection control, reprocessing costs, and device durability. A notable differentiator for the aScope 5 Uretero is its use of bio-attributed plastics (Bio-ABS), derived in part from recycled feedstock. According to the company, these materials reduce the carbon footprint of the ureteroscope handle by up to 70 percent compared to conventional plastics, reflecting emerging priorities around sustainability in medical device design. Clinicians involved in early use have highlighted the device’s enhanced optics, compact profile, and ease of handling as advantages that align with procedural needs in contemporary endourology practice.

3. Next Move Strategy Consulting - Opinion, Impact and Near-Term Prospects

Next Move Strategy Consulting interprets these developments as clear markers of a maturing Ureteroscope Market, one in which clinical value, workflow impact, and sustainability increasingly influence adoption decisions.

• Innovation balanced with workflow value: Integrated systems like Dornier’s reflect growing demand for devices that streamline procedures end-to-end rather than improve a single metric in isolation.

• Single-use solutions gaining traction: Ambu’s clearance underscores continued momentum in disposable ureteroscopy tools, driven by infection control priorities and predictable operating costs especially in high-volume settings.

• Sustainability as a differentiator: The use of bio-derived materials signals that environmental impact and lifecycle footprint are becoming meaningful factors in device selection, especially among large health systems.

• Regulatory and reimbursement dynamics: Devices poised for rapid clinical uptake will be those that not only meet regulatory standards but also align with reimbursement pathways and hospital economics.

• Value beyond devices: Services such as procedural training, clinical data collection, and integration support are expected to grow as complementary revenue streams for manufacturers.

4. Practical Suggestions for Stakeholders

• Hospitals and surgical centers should assess both reusable and single-use ureteroscopes within the context of procedural volume, infection control priorities, and total cost of ownership.

• Device manufacturers should invest in data generation that demonstrates workflow efficiency, clinical outcomes, and sustainability benefits to support adoption and payer coverage.

• Investors should monitor companies that combine performance innovation with environmentally responsible manufacturing and clear regulatory pathways.

• Policy makers and professional societies should advance guidelines that reflect both clinical efficacy and environmental considerations in device selection.

Conclusion

The recent introductions by Dornier MedTech America and Ambu mark a turning point in the Ureteroscope Market, highlighting the dual forces of innovation and practical adoption. As the market evolves, success will be defined not only by technological advancement but also by how well devices integrate into clinical workflows, meet sustainability expectations, and deliver value across the care continuum. Manufacturers and healthcare organizations that prioritize usability, regulatory readiness, and lifecycle performance will be best positioned to lead the next phase of growth in ureteroscopy technology.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to providing strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes NMSC different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more information please contact:

Next Move Strategy Consulting

5th Floor 867

Boylston St, STE 500,

Boston, MA 02116, U.S.

E-Mail: [email protected]

Direct: +1-857-758-5017

Website: www.nextmsc.com